Literature DB >> 16498489

Atypicality of atypical antipsychotics.

Andrew Farah1.   

Abstract

OBJECTIVE: To review the current definition of atypicality, discuss the unique features of each atypical antipsychotic, and determine whether the available drugs in this class really meet the classical definition of atypicality. DATA SOURCES: A PubMed search was conducted to identify literature on the subject of this review, supported by additional articles based on the author's clinical knowledge and experience. STUDY SELECTION AND DATA EXTRACTION: Relevant references were extracted and summarized in order to meet the objective of the article. DATA SYNTHESIS: Atypical antipsychotics are considered a major advance over conventional antipsychotics, primarily because they offer effective treatment alternatives that are relatively free of extrapyramidal symptoms. In fact, the term atypicality was originally used to describe antipsychotic agents with a minimal risk of causing extrapyramidal symptoms. However, over the years the definition has been modified such that there is currently no consensus on a true definition of atypicality for these agents. Each of the atypical antipsychotics (clozapine, risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole) commercially available in the United States is unique in terms of its pharmacologic profile, differing with respect to receptor-binding affinity, mechanism of action, and adverse events. Of the available atypical antipsychotics, clozapine and quetiapine have shown the lowest propensity to cause extrapyramidal symptoms. Although the risk of extra-pyramidal symptoms is lower with risperidone and olanzapine than with conventional antipsychotics, risk increases with dose escalation. Data for ziprasidone indicate that the risk of extrapyramidal symptoms may be similar to that of risperidone and olanzapine. There is a concern of akathisia with aripiprazole; however, more experience with this agent is needed before definitive conclusions are made.
CONCLUSION: If the definition of "atypical" antipsychotic is considered to be freedom from extrapyramidal symptoms, then, based on a comprehensive review of available data and clinical experience, clozapine and quetiapine appear to be the only true atypicals.

Entities:  

Year:  2005        PMID: 16498489      PMCID: PMC1324958          DOI: 10.4088/pcc.v07n0602

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN: 1523-5998


  57 in total

1.  Possible risperidone-induced tardive dystonia.

Authors:  R Narendran; C M Young; M T Pato
Journal:  Ann Pharmacother       Date:  2000-12       Impact factor: 3.154

2.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

3.  A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography.

Authors:  Steven G Potkin; Gustavo Alva; Kirsten Fleming; Ravi Anand; David Keator; Danilo Carreon; Michael Doo; Yi Jin; Joseph C Wu; James H Fallon
Journal:  Am J Psychiatry       Date:  2002-02       Impact factor: 18.112

4.  The long-term effect of quetiapine (Seroquel TM ) monotherapy on weight in patients with schizophrenia.

Authors:  M Brecher; I W Rak; K Melvin; A M Jones
Journal:  Int J Psychiatry Clin Pract       Date:  2000       Impact factor: 1.812

5.  The new generation of antipsychotic drugs: how atypical are they?

Authors:  Jeffrey M. Goldstein
Journal:  Int J Neuropsychopharmacol       Date:  2000-12       Impact factor: 5.176

Review 6.  Atypical antipsychotics. Part I: Pharmacology, pharmacokinetics, and efficacy.

Authors:  J S Markowitz; C S Brown; T R Moore
Journal:  Ann Pharmacother       Date:  1999-01       Impact factor: 3.154

7.  D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients.

Authors:  A L Nordström; L Farde; S Nyberg; P Karlsson; C Halldin; G Sedvall
Journal:  Am J Psychiatry       Date:  1995-10       Impact factor: 18.112

Review 8.  Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.

Authors:  Christoph U Correll; Stefan Leucht; John M Kane
Journal:  Am J Psychiatry       Date:  2004-03       Impact factor: 18.112

9.  A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone.

Authors:  David Mamo; Shitij Kapur; C M Shammi; George Papatheodorou; Steve Mann; François Therrien; Gary Remington
Journal:  Am J Psychiatry       Date:  2004-05       Impact factor: 18.112

10.  A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.

Authors:  Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Clarnette; Emma Lee; Ben Lyons; Fred Grossman
Journal:  J Clin Psychiatry       Date:  2003-02       Impact factor: 4.384

View more
  22 in total

1.  Antidepressant and Antipsychotic Drugs.

Authors:  Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2010-12-01

Review 2.  [Antipsychotic drug-induced changes in metabolism].

Authors:  Julia Engl; Alexander Tschoner; Markus Laimer; Maria Rettenbacher; W Wolfgang Fleischhacker; Josef R Patsch; Christoph Ebenbichler
Journal:  Wien Klin Wochenschr       Date:  2006-05       Impact factor: 1.704

3.  Clozapine administration modifies neurotensin effect on synaptosomal membrane Na+, K+ -ATPase activity.

Authors:  María G López Ordieres; Georgina Rodríguez de Lores Arnaiz
Journal:  Neurochem Res       Date:  2009-12       Impact factor: 3.996

Review 4.  Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.

Authors:  Katharina Stegmayer; Sebastian Walther; Peter van Harten
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

Review 5.  Clozapine, atypical antipsychotics, and the benefits of fast-off D2 dopamine receptor antagonism.

Authors:  Georges Vauquelin; Sophie Bostoen; Patrick Vanderheyden; Philip Seeman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-02-14       Impact factor: 3.000

Review 6.  Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia.

Authors:  James E Frampton
Journal:  Drugs       Date:  2010-12-03       Impact factor: 9.546

7.  New insights in the management of antipsychotics in the treatment of schizophrenia in a patient with prolactinoma: a case report and review of the literature.

Authors:  Elvis Henrique Santos Andrade; Pedro Mario Pan; Paula F Ramalho da Silva; Ary Gadelha
Journal:  Case Rep Med       Date:  2010-11-10

Review 8.  Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

9.  The use of second-generation antipsychotics and the changes in physical growth in children and adolescents with perinatally acquired HIV.

Authors:  Suad Kapetanovic; Lisa Aaron; Grace Montepiedra; Patricia A Sirois; James M Oleske; Kathleen Malee; Deborah A Pearson; Sharon L Nichols; Patricia A Garvie; John Farley; Molly L Nozyce; Mark Mintz; Paige L Williams
Journal:  AIDS Patient Care STDS       Date:  2009-11       Impact factor: 5.078

Review 10.  Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence.

Authors:  Chi-Un Pae; Alessandro Serretti; Ashwin A Patkar; Praksh S Masand
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.